Nathan Valentine
Family · Aberdeen, WANPI 1154707552
Payments from drug & device makers
Across 232 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$706
- GSK$388
- AstraZeneca$387
- Pfizer$353
- Boehringer Ingelheim$264
- AbbVie$243
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,986100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 54 | $706 |
| GSK | 19 | $388 |
| AstraZeneca(2 entities) | 22 | $387 |
| Pfizer | 19 | $353 |
| Boehringer Ingelheim | 11 | $264 |
| AbbVie | 16 | $243 |
| Novo Nordisk | 16 | $230 |
| Sanofi-aventis U.S. LLC | 12 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $153 |
| Novartis | 7 | $144 |
| Bayer | 7 | $121 |
| Phathom Pharmaceuticals, Inc. | 6 | $116 |
| Johnson & Johnson | 4 | $97 |
| Abbott | 4 | $80 |
| Sanofi Pasteur Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $73 |
| Shield Therapeutics Inc | 3 | $56 |
| Mylan Specialty L.p. | 3 | $54 |
| Astellas Pharma US Inc | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Viatris Specialty LLC | 2 | $40 |
| Exact Sciences | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Hologic Sales And Service, LLC | 1 | $15 |
How this compares
$3,986 in reported general payments places this provider in the 90th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 81 | $93,048 |
| TrulicityDulaglutide | 61 | $76,201 |
| OzempicSemaglutide | 38 | $39,201 |
| MounjaroTirzepatide | 26 | $38,202 |
| XareltoRivaroxaban | 37 | $32,012 |
| JanuviaSitagliptin Phosphate | 15 | $22,290 |
| JardianceEmpagliflozin | 22 | $22,019 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $21,539 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $17,950 |
| Repatha SureclickEvolocumab | 32 | $17,715 |
| Spiriva RespimatTiotropium Bromide | 17 | $15,436 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $13,242 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $10,573 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $5,995 |
| BrilintaTicagrelor | 11 | $5,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $73 | $114,40487 claims |
| PfizerEliquis, Abrysvo | $353 | $96,75093 claims |
| Novo NordiskOzempic | $230 | $39,20138 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $264 | $37,45639 claims |
| Johnson & JohnsonXarelto | $97 | $32,01237 claims |
| GSKTrelegy Ellipta | $388 | $21,53916 claims |
| AstraZenecaBrilinta | $387 | $5,88711 claims |
| Sanofi-aventis U.S. LLCLantus | $175 | $3,97913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,706 family providers in Washington.
Other family in Aberdeen
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.